52049
document
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis . This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis . Zoledronic acid is significantly more effective than risedronate in increasing lumbar spine ( LS ) bone mineral density ( BMD ) in both prevention and treatment of glucocorticoid-induced osteoporosis . Introduction In patients on glucocorticoids , a single zoledronic acid infusion significantly increased BMD versus daily oral risedronate . We assessed treatment effect on LS BMD in different patient subgroups at month 12 that contributed to the risk of osteoporosis in addition to glucocorticoids . Methods Patients randomized to a single IV infusion of zoledronic acid 5 mg or risedronate ( 5 mg/day ) and stratified based on glucocorticoids duration [ treatment ( > 3 months ) and prevention ( ≤ 3 months ) subpopulations ] were subgrouped by age ; gender ; menopausal status in women ; dose and duration of prednisone during the trial ; and baseline serum 25-OH vitamin D , LS BMD T-score , creatinine clearance , and concomitant medication use . Results At month 12 , zoledronic acid significantly increased LS BMD versus risedronate in patients ≤ 74 years ( P < 0.05 ) in the treatment and 65-74 years ( P = 0.0008 ) in the prevention subpopulation . At month 12 , zoledronic acid significantly increased LS BMD versus risedronate in both subpopulations irrespective of gender ( all P < 0.05 ) , cumulative prednisone dose ( all P < 0.01 ) , and postmenopausal status ( all P < 0.05 ) . In premenopausal women , in both subpopulations , zoledronic acid significantly increased total hip BMD ( all P < 0.05 ) versus risedronate at month 12 but not LS BMD . Osteoporotic patients in the prevention ( P=0.0189 ) and osteopenic patients in the treatment subpopulation ( P=0.0305 ) showed significant LS BMD increases with zoledronic acid versus risedronate at month 12 . Conclusions This post hoc analysis suggests that zoledronic acid is significantly more effective than risedronate in increasing LS BMD in prevention and treatment of glucocorticoid-induced osteoporosis across a wide range of patients .
52050
Intervention_Pharmacological
zoledronic acid
52051
Intervention_Pharmacological
risedronate
52052
Intervention_Pharmacological
zoledronic acid
52053
Intervention_Pharmacological
Zoledronic acid
52054
Intervention_Pharmacological
risedronate
52055
Intervention_Pharmacological
glucocorticoids
52056
Intervention_Pharmacological
zoledronic acid
52057
Intervention_Pharmacological
risedronate
52058
Intervention_Pharmacological
zoledronic acid
52059
Intervention_Pharmacological
risedronate
52060
Intervention_Pharmacological
zoledronic acid
52061
Intervention_Pharmacological
risedronate
52062
Outcome_Physical
lumbar spine bone mineral density
52063
Outcome_Physical
lumbar spine ( LS ) bone mineral density ( BMD )
52064
Outcome_Physical
BMD
52065
Outcome_Physical
LS BMD
52066
Participant_Condition
patients on glucocorticoids